Ramucirumab and durvalumab for previously treated, advanced non–small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ)

Yung Jue Bang*, Talia Golan, Laetitia Dahan, Siqing Fu, Victor Moreno, Keunchil Park, Ravit Geva, Filippo De Braud, Zev A. Wainberg, Martin Reck, Laura Goff, Naomi Laing, Gu Mi, Joana M. Oliveira, Heather Wasserstrom, Chia Chi Lin

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Ramucirumab and durvalumab for previously treated, advanced non–small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ)'. Together they form a unique fingerprint.

Medicine & Life Sciences